For the first question, there are currently two ongoing phase III clinical trials that are comparing selpercatinib or pralsetinib to platinum-based chemotherapy with or without pembrolizumab as an initial treatment for advanced or metastatic RET+ NSCLC patients (Table 3). This evidence concerns the gene RET and non-small cell lung carcinoma.